HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Paola Menichini Selected Research

B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

10/2022MiR-146b-5p regulates IL-23 receptor complex expression in chronic lymphocytic leukemia cells.
4/2021Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
1/2021Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
3/2020NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcome.
1/2020Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Paola Menichini Research Topics

Disease

19Neoplasms (Cancer)
12/2023 - 08/2003
5B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
10/2022 - 01/2020
3Neuroblastoma
02/2021 - 01/2017
2Carcinogenesis
04/2023 - 04/2014
2Neoplasm Metastasis (Metastasis)
02/2021 - 01/2019
2Disease Progression
01/2021 - 10/2020
1Colonic Neoplasms (Colon Cancer)
01/2022
1Hematologic Neoplasms (Hematological Malignancy)
01/2021
1Melanoma (Melanoma, Malignant)
10/2017
1Breast Neoplasms (Breast Cancer)
11/2010
1Genomic Instability
07/2010
1DNA Repair-Deficiency Disorders (Chromosome Instability Syndromes)
03/2008
1Nijmegen Breakage Syndrome
10/2005
1Ataxia Telangiectasia (Louis Bar Syndrome)
10/2005

Drug/Important Bio-Agent (IBA)

7Proteins (Proteins, Gene)FDA Link
12/2023 - 01/2011
4MicroRNAs (MicroRNA)IBA
04/2023 - 01/2018
32,2- bis(hydroxymethyl)- 1- azabicyclo(2,2,2,)octan- 3- oneIBA
01/2021 - 11/2010
2AntioxidantsIBA
04/2023 - 01/2022
2ibrutinibIBA
04/2021 - 01/2021
2Rituximab (Mabthera)FDA Link
04/2021 - 01/2021
2Protein Isoforms (Isoforms)IBA
03/2020 - 04/2014
2Transcription Factors (Transcription Factor)IBA
10/2017 - 01/2011
2methyl lexitropsinIBA
07/2010 - 03/2008
2DNA (Deoxyribonucleic Acid)IBA
04/2007 - 08/2003
1PTC596IBA
12/2023
1Mutant Proteins (Protein, Mutant)IBA
10/2023
1Messenger RNA (mRNA)IBA
04/2023
1Oxidants (Oxidizing Agents)IBA
04/2023
1spirooxindoleIBA
01/2023
1Interleukin-23 (Interleukin 23)IBA
10/2022
1idelalisibIBA
04/2021
1Bendamustine HydrochlorideFDA Link
01/2021
1Biomarkers (Surrogate Marker)IBA
12/2019
1Etoposide (VP 16)FDA LinkGeneric
01/2018
1Oncogene Proteins (Oncogene Protein)IBA
01/2018
1gambogic acidIBA
02/2017
1RNA (Ribonucleic Acid)IBA
01/2017
1RNA Polymerase IIIIBA
01/2017
1LuciferasesIBA
01/2011
1N3-methyladenineIBA
07/2010
1DNA-Directed DNA Polymerase (Polymerases, DNA)IBA
03/2008
1Peptides (Polypeptides)IBA
08/2006
1Sirolimus (Rapamycin)FDA Link
10/2005
1Codon (Codons)IBA
08/2003

Therapy/Procedure

5Therapeutics
02/2021 - 01/2019
2Drug Therapy (Chemotherapy)
01/2021 - 10/2020